128 related articles for article (PubMed ID: 15279546)
1. Treatment of acute hepatitis C.
Santantonio T
Curr Pharm Des; 2004; 10(17):2077-80. PubMed ID: 15279546
[TBL] [Abstract][Full Text] [Related]
2. Therapy of acute hepatitis C: a review of literature.
Santantonio T; Fasano M
Curr Pharm Des; 2008; 14(17):1686-9. PubMed ID: 18673192
[TBL] [Abstract][Full Text] [Related]
3. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
Fabrizi F; Dixit V; Martin P; Messa P
J Viral Hepat; 2011 Jul; 18(7):e263-9. PubMed ID: 21108701
[TBL] [Abstract][Full Text] [Related]
4. [Recent trends in the therapy of hepatitis C].
Meschini A; Lucchetta MC; Fontana M; Nocchi S; Pace A; Grassi M
Clin Ter; 2003; 154(3):181-91. PubMed ID: 12910808
[TBL] [Abstract][Full Text] [Related]
5. PEG-interferon in acute and chronic hepatitis C: a review.
Palumbo E
Am J Ther; 2009; 16(6):573-8. PubMed ID: 19433975
[TBL] [Abstract][Full Text] [Related]
6. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
7. [Antiviral therapy of hepatitis C].
Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
[TBL] [Abstract][Full Text] [Related]
8. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
Aghemo A; Rumi MG; Colombo M
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
[TBL] [Abstract][Full Text] [Related]
9. Interferon-based therapy of hepatitis C.
Chevaliez S; Pawlotsky JM
Adv Drug Deliv Rev; 2007 Oct; 59(12):1222-41. PubMed ID: 17869375
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of hepatitis C virus infection].
Zeuzem S
Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
[TBL] [Abstract][Full Text] [Related]
11. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.
Niederau C; Mauss S; Böker K; Lutz T; Heyne R; Moog G; John C; Witthöft T; Alshuth U; Hüppe D
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):65-73. PubMed ID: 23751351
[TBL] [Abstract][Full Text] [Related]
12. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.
Xirouchakis E; Triantos C; Manousou P; Sigalas A; Calvaruso V; Corbani A; Leandro G; Patch D; Burroughs A
J Viral Hepat; 2008 Oct; 15(10):699-709. PubMed ID: 18673428
[TBL] [Abstract][Full Text] [Related]
13. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
Horváth G; Tolvaj G; Halász T; Stotz G
Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.
Dintsios CM; Haverkamp A; Wiegand J; Gerlach T; Wedemeyer H; Pape G; Manns MP; Krauth C
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):278-88. PubMed ID: 19550347
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
Su H; Liu Z; Sun Y; Li H; Zhou S; Zhou X; Gao Y; Tang R; Zhang D; Zhang M
Ann Transplant; 2015 May; 20():263-8. PubMed ID: 25975740
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.
Chen J; Shi J; Xie WF; Zeng X; Lin Y
Int J Infect Dis; 2012 Oct; 16(10):e748-52. PubMed ID: 22836046
[TBL] [Abstract][Full Text] [Related]
19. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.
Santantonio T; Fasano M; Sagnelli E; Tundo P; Babudieri S; Fabris P; Toti M; Di Perri G; Marino N; Pizzigallo E; Angarano G;
Hepatology; 2014 Jun; 59(6):2101-9. PubMed ID: 24442928
[TBL] [Abstract][Full Text] [Related]
20. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
